STANISLAW CHORZEPA: Open Payments
NPI 1750375127 · KENSINGTON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$726 in 36 payments from 14 companies in 2025. Trend: 2023 $835 · 2024 $827 · 2025 $726
Food & beverage: $726
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 5 | $110 |
| ABBVIE INC. | 4 | $95 |
| Boston Scientific Corporation | 3 | $93 |
| Phathom Pharmaceuticals, Inc. | 6 | $84 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $81 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $46 |
| Novo Nordisk Inc | 2 | $40 |
| Janssen Pharmaceuticals, Inc | 2 | $36 |
| Amgen Inc. | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
Products named: JARDIANCE, WATCHMAN Access System, VOQUEZNA, VRAYLAR, XIFAXAN, SPRAVATO, OTEZLA, BREZTRI.
Industry payments across CT — which companies pay providers there.
